Yeda Research and Develpment & Co. Ltd

Applied Research Systems Ars Holding N.v.

The Weizmann Institute of Science

Kadimastem Ltd.

Judith Chebath

Michel Revel

Rosalia Kaufman

Michal Izrael

Tsvee Lapidot

Orit Kollet

Alon Levy

Carolina Abramovitch

Ursula Boschert

Arik Hasson

Kfir Molakandov

Peter Lonai

Hagit Krug

Shalom Haggiag

Peilin Zhang

Guy Slutsky

Marina Pizzi

PierFranco Spano

Robert Halimi

Arye Hasson

Molakandov Kfir

Peilin Molecular Genetics Dept Zhang

A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity.

Methods of generating glial and neuronal cells and use of same for the treatment of medical conditions of the CNS

A method of generating islet cells from pluripotent stem cells is disclosed. The method comprises: (a) culturing the pluripotent stem cells in a differentiation medium so as to differentiate the pluripotent stem cells into endoderm cells; and (b) culturing the endoderm cells in a medium comprising at least one growth factor, a cAMP inducer and retinoic acid (RA), said at least one growth factor being selected from the group consisting of FGF10, bFGF and FGF7 so as to generate further differentiated cells; and (c) culturing the further differentiated cells in a medium comprising a maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells from pluripotent stem cells. Further methods of generating islet cells are also disclosed, isolated cell populations comprising same and uses thereof.

Insulin producing cells derived from pluripotent stem cells

Methods of generating mature oligodendrocytes

The present invention is generally in the field of neurological diseases and disorders, particular in the field of neurodegenerative diseases in which the myelin cover of nerves is lost. IL6R/IL6 chimera is used to promote the formation of oligodendrocytes from embryonic stem cells for treatment of neurodegenerative diseases or posttraumatic nerve damage.

Method of generating oligodendrocytes from neurosphere cells

The invention relates to the use of IL-6R/IL-6 chimera in chemotherapy induced neuropathy.

IL6R/IL6 chimera for therapy of chemotherapy-induced peripheral neuropathy

The present invention provides for the use of IL6R/IL6 chimera for the manufacture of medicaments for the treatment of neurological diseases and disorders.

Use of il6r/il6 chimera in nerve cell regeneration

Novel proteins IR1B1 and IR1B4 have been isolated which bind to the type I IFN receptor IFNAR1 and function in the cellular response to IFNs. DNA encoding such proteins in either the sense or anti-sense orientation can be administered to either enhance or inhibit the cellular response to IFNs. Antibodies to the proteins can be used for isolation of the new protein or for immunodetection thereof.

IFN receptor 1 binding proteins

Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.

Nucleic acids encoding chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof

IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons

The invention relates to the use of IL6RIL6 chimera in the treatment and prevention of neurological diseases and disorders.

IL6RIL6 chimera for the treatment of neurodegenerative diseases

Chimeric interleukin-6 soluble receptor/ligand proteins

Novel peptides derived from the gp80 subunit of the IL-6 receptor system which inhibit the activity of IL-6 are provided.

Synthetic peptides that inhibit IL-6 activity

Human DNA encoding enzymes having (2'-5') oligo A synthetase has been sequenced. The amino acid sequences of the enzymes have been deduced. Antigenic peptides have been prepared and have been used to raise antibodies which recognize and immunoprecipitate the 40 kd, 46 kd, 67 kd and 100 kd forms of (2'-5') oligo A synthetase. Methods of monitoring interferon activity in a subject are presented.

Growing community of inventors

Rehovot, Israel

Judith Chebath